Response to Letter to the Editor from Hao and Xue: "Checkpoint Inhibitor-associated Autoimmune Diabetes Mellitus Is Characterized by C-Peptide Loss and Pancreatic Atrophy".

MLA

Wu, Linda, et al. “Response to Letter to the Editor from Hao and Xue: ‘Checkpoint Inhibitor-Associated Autoimmune Diabetes Mellitus Is Characterized by C-Peptide Loss and Pancreatic Atrophy.’” The Journal of Clinical Endocrinology and Metabolism, vol. 110, no. 2, Jan. 2025, pp. e552–53. EBSCOhost, https://doi.org/10.1210/clinem/dgae555.

APA

Wu, L., Carlino, M. S., Brown, D. A., Long, G. V., Clifton-Bligh, R., Mellor, R., Moore, K., Sasson, S. C., Menzies, A. M., Tsang, V., & Gunton, J. E. (2025). Response to Letter to the Editor from Hao and Xue: “Checkpoint Inhibitor-associated Autoimmune Diabetes Mellitus Is Characterized by C-Peptide Loss and Pancreatic Atrophy.” The Journal of Clinical Endocrinology and Metabolism, 110(2), e552–e553. https://doi.org/10.1210/clinem/dgae555

Chicago

Wu, Linda, Matteo Salvatore Carlino, David Alexander Brown, Georgina Venetia Long, Roderick Clifton-Bligh, Rhiannon Mellor, Krystal Moore, et al. 2025. “Response to Letter to the Editor from Hao and Xue: ‘Checkpoint Inhibitor-Associated Autoimmune Diabetes Mellitus Is Characterized by C-Peptide Loss and Pancreatic Atrophy.’” The Journal of Clinical Endocrinology and Metabolism 110 (2): e552–53. doi:10.1210/clinem/dgae555.